AroCell AB: Research poster on prostate cancer has been accepted by the American Association for Cancer Research (AARC)
January 24 2017 - 5:45AM
AroCell AB (publ) announces today
that a research poster submitted by Kiran Kumar J et al entitled
"The AroCell TK 210 ELISA may complement Pro PSA and the Prostate
Health Index in differentiating pre-cancerous and cancerous
conditions in prostate cancer" was accepted by the AARC for
presentation at their annual meeting in April 2017.
The purpose of this study was to compare the
AroCell TK 210 ELISA with PSA, free PSA, pro PSA and PHI (prostate
health index) in men with pre-cancerous conditions and patients
with confirmed prostate cancer.
Serum samples from 94 patients with known PSA
values for prostate cancer were collected by the University Medical
Centre, Ljubljana. Overall, the AroCell TK 210 ELISA showed
significant correlation with PHI (r=032, P=0.0017) and pro PSA
(r021 P=0.044) but not with free PSA or PSA.
CEO Jan Stålemark states "We are delighted that
this preliminary study demonstrates that serum TK1 assayed with
AroCell TK 210 ELISA can differentiate between pre-cancerous
conditions and prostate cancer patients with a similar accuracy to
that of pro PSA. Further clinical studies will establish the
capacity of AroCell TK 210 ELISA to complement pro PSA and PHI in
distinguishing between pre-cancerous and prostate cancer,
potentially providing another tool in prostate cancer
management".
For additional
information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com
This information is information
that AroCell is obliged to make public pursuant to the EU Market
Abuse Regulation and the Securities Markets Act. The information
was submitted for publication, through Jan Stålemark, at 11:45 CET
on 24 January 2017.
About AroCell
AroCell AB (publ) is a Swedish
company that develops standardized modern blood tests to support
the prognosis and follow up of cancer patients. AroCell's new
technology is based on patented methods to measure TK1 protein
levels, which provide valuable information about the speed of cell
turnover. A tumor has high cell turnover (speed of cell division
and cell death) and as a result TK1 can be detected in the blood
with a simple laboratory test, called TK 210 ELISA. The test
provides valuable clinical information for prognosis and
optimization of treatment strategy. The test may also be used for
monitoring disease relapse. AroCell (AROC) is listed at Nasdaq
First North and has about 2,600 shareholders. For more information,
please see www.arocell.com. Redeye AB is
AroCell:s Certified Adviser.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: AroCell AB via Globenewswire
Archrock (NYSE:AROC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Archrock (NYSE:AROC)
Historical Stock Chart
From Sep 2023 to Sep 2024